CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Download All
Learn how global experts are leveraging the latest data on CDK4/6 inhibitors in patients with HR+/HER2- EBC. Watch the on-demand webcast from the live webinar, download the slides, and listen to the podcast featuring expert reviews of the most important data on early breast cancer from ESMO Breast 2021.
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH

On-Demand Webcast

Watch this on-demand webcast of a live CCO webinar where global experts discuss the latest data on CDK4/6 inhibitors in the treatment of patients with early-stage HR+/HER2- breast cancer.

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings